Prognostic Value of a Multimarker Approach for Patients Presenting to Hospital With Acute Chest Pain
To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assess...
Saved in:
Published in | The American journal of cardiology Vol. 103; no. 1; pp. 22 - 28 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
2009
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid–binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal–pro-brain natriuretic peptide [NT–pro-BNP]), hemostatic activity (fibrinogen and d -dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase–9, pregnancy-associated plasma protein–A, and soluble CD40 ligand). A ≥12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT ≥0.03 μg/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, d -dimer, H-FABP, NT–pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT–pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT–pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT–pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. |
---|---|
AbstractList | To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid-binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal-pro-brain natriuretic peptide [NT-pro-BNP]), hemostatic activity (fibrinogen and D-dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase-9, pregnancy-associated plasma protein-A, and soluble CD40 ligand). A >or=12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT >or=0.03 microg/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, D-dimer, H-FABP, NT-pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT-pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT-pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT-pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid–binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal–pro-brain natriuretic peptide [NT–pro-BNP]), hemostatic activity (fibrinogen and d -dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase–9, pregnancy-associated plasma protein–A, and soluble CD40 ligand). A ≥12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT ≥0.03 μg/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, d -dimer, H-FABP, NT–pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT–pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT–pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT–pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid-binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal-pro-brain natriuretic peptide [NT-pro-BNP]), hemostatic activity (fibrinogen and d-dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase-9, pregnancy-associated plasma protein-A, and soluble CD40 ligand). A ≥12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT ≥0.03 ...g/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, d-dimer, H-FABP, NT-pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT-pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT-pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT-pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. (ProQuest: ... denotes formulae/symbols omitted.) To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid–binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal–pro-brain natriuretic peptide [NT–pro-BNP]), hemostatic activity (fibrinogen and d -dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase–9, pregnancy-associated plasma protein–A, and soluble CD40 ligand). A ≥12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT ≥0.03 μg/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, d -dimer, H-FABP, NT–pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT–pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT–pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT–pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664 patients presenting to 2 coronary care units with ischemic-type chest pain was conducted over 3 years beginning in 2003. Patients were assessed on admission for clinical characteristics, electrocardiographic findings, renal function, cardiac troponin T (cTnT), markers of myocyte injury (heart fatty acid-binding protein [H-FABP] and glycogen phosphorylase BB), neurohormonal activation (N-terminal-pro-brain natriuretic peptide [NT-pro-BNP]), hemostatic activity (fibrinogen and D-dimer), and vascular inflammation (high-sensitivity C-reactive protein, myeloperoxidase, matrix metalloproteinase-9, pregnancy-associated plasma protein-A, and soluble CD40 ligand). A >or=12-hour cTnT sample was also obtained. Myocardial infarction (MI) was defined as peak cTnT >or=0.03 microg/L. Patients were followed for 1 year from the time of admission. The primary end point was death or MI. Elevated fibrinogen, D-dimer, H-FABP, NT-pro-BNP, and peak cTnT were predictive of death or MI within 1 year (unadjusted odds ratios 2.5, 3.1, 5.4, 5.4, and 6.9, respectively). On multivariate analysis, H-FABP and NT-pro-BNP were selected, in addition to age, peak cTnT, and left ventricular hypertrophy on initial electrocardiography, as significant independent predictors of death or MI within 1 year. Patients without elevations of H-FABP, NT-pro-BNP, or peak cTnT formed a very low risk group in terms of death or MI within 1 year. A very high risk group had elevations of all 3 biomarkers. In conclusion, the measurement of H-FABP and NT-pro-BNP at the time of hospital admission for patients with ischemic-type chest pain adds useful prognostic information to that provided by the measurement of baseline and 12-hour cTnT. |
Author | Menown, Ian B.A., MD Smith, Bernie, RGN Young, Ian S., MD McCann, Conor J., MD Adgey, Jennifer A., MD Sharpe, Peter C., MD Moore, Michael J., MD Owens, Colum G., MD Glover, Ben M., MD McEneny, Jane, PhD |
Author_xml | – sequence: 1 fullname: McCann, Conor J., MD – sequence: 2 fullname: Glover, Ben M., MD – sequence: 3 fullname: Menown, Ian B.A., MD – sequence: 4 fullname: Moore, Michael J., MD – sequence: 5 fullname: McEneny, Jane, PhD – sequence: 6 fullname: Owens, Colum G., MD – sequence: 7 fullname: Smith, Bernie, RGN – sequence: 8 fullname: Sharpe, Peter C., MD – sequence: 9 fullname: Young, Ian S., MD – sequence: 10 fullname: Adgey, Jennifer A., MD |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21003227$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19101224$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkm2L1DAQx4OceHunH0EJgr7bdZK0afNGWRb1hBMXfHwX0nR6m71usyapcN_elC0n3BthIBnym4f8Zy7I2eAHJOQ5gxUDJt_sV-awtya0Kw5Qrybj8hFZsLpSS6aYOCMLAOBLxQp1Ti5i3GeXsVI-Ief5HRjnxYK02-BvBh-Ts_SH6UekvqOGfh775A4m3GKg6-MxeGN3tPOBbk1yOKRItwFjvrjhhiZPr3w8umR6-tOlHV3bMSHd7DCmHOCGp-RxZ_qIz-bzknz_8P7b5mp5_eXjp836emmLqkzLwrScIbBKSqhRdaAqUXJRKcHLxpiOFxXYWjHOagFV09aNRaYk2qZphJKduCSvT3lzw7_HXF0fXLTY92ZAP0YtZVVIJesMvnwA7v0Yhtyb5gJEDbJmGSpPkA0-xoCdPoZJkzvNQE8z0Hs9z0BPM9CTcZnjXszJx-aA7b-oWfQMvJoBE63pu2AG6-I9xxmA4LzK3LsTh1mzPw6DjjaLb7F1AW3SrXf_beXtgwy2d4PLRW_xDuP9p5mOXIP-Oi3MtC9QAytY-Uv8BaXIvLM |
CODEN | AJCDAG |
CitedBy_id | crossref_primary_10_1016_j_jelectrocard_2013_02_007 crossref_primary_10_1177_1076029620944492 crossref_primary_10_1089_neu_2012_2791 crossref_primary_10_1136_heartjnl_2013_305253 crossref_primary_10_1016_j_jelectrocard_2011_03_001 crossref_primary_10_1586_erc_11_2 crossref_primary_10_3109_1354750X_2011_576431 crossref_primary_10_1136_heartjnl_2013_304716 crossref_primary_10_1373_jalm_2016_022418 crossref_primary_10_1016_j_amjmed_2011_05_026 crossref_primary_10_1016_j_jjcc_2011_07_008 crossref_primary_10_1371_journal_pone_0055175 crossref_primary_10_1007_s12325_009_0032_7 crossref_primary_10_1515_cclm_2011_753 crossref_primary_10_3390_cells13030289 crossref_primary_10_2217_clp_13_87 crossref_primary_10_1373_clinchem_2011_166827 crossref_primary_10_3390_jcdd9080242 crossref_primary_10_1177_2048872613484688 crossref_primary_10_1016_j_ijcard_2012_01_081 crossref_primary_10_1016_j_amjcard_2012_06_020 crossref_primary_10_1080_07853890_2020_1800075 crossref_primary_10_2217_bmm_10_16 crossref_primary_10_1016_j_cca_2014_08_011 crossref_primary_10_1016_j_amjcard_2009_02_001 crossref_primary_10_1016_S0300_8932_10_70140_8 crossref_primary_10_1080_1354750X_2017_1397194 crossref_primary_10_1016_j_ahj_2010_05_002 crossref_primary_10_1016_j_arcmed_2011_07_004 crossref_primary_10_1016_j_ehj_2012_06_004 crossref_primary_10_1373_clinchem_2011_165811 crossref_primary_10_3109_13547500903560065 crossref_primary_10_1136_postgradmedj_2019_136409 crossref_primary_10_1097_MCA_0b013e328338cd1f crossref_primary_10_1016_j_annemergmed_2010_03_005 crossref_primary_10_1016_j_ajem_2010_11_022 crossref_primary_10_1111_aor_12078 crossref_primary_10_1155_2019_2872607 crossref_primary_10_1007_s00380_010_0080_6 crossref_primary_10_1097_MCA_0b013e32833db539 crossref_primary_10_3109_17482940903578980 crossref_primary_10_1002_prca_201000125 crossref_primary_10_1371_journal_pone_0098626 crossref_primary_10_1016_j_ijcard_2011_06_066 crossref_primary_10_1016_j_ahj_2012_12_020 crossref_primary_10_1016_j_redar_2014_02_011 crossref_primary_10_2217_bmm_2015_0029 crossref_primary_10_1016_j_clinbiochem_2018_04_021 crossref_primary_10_1016_j_jacbts_2016_10_003 crossref_primary_10_1016_j_clinbiochem_2009_09_026 crossref_primary_10_1016_j_clinbiochem_2011_05_029 crossref_primary_10_1016_j_jacc_2009_12_062 crossref_primary_10_1016_j_amjcard_2010_12_006 crossref_primary_10_3390_antiox12030645 crossref_primary_10_1097_GCO_0b013e3283339a65 crossref_primary_10_1177_2047487315619733 crossref_primary_10_2217_bmm_13_6 crossref_primary_10_1016_j_redare_2014_12_001 crossref_primary_10_1309_AJCPBIK3G4BWEJKO crossref_primary_10_1007_s11239_013_1044_3 crossref_primary_10_1007_s12265_023_10425_2 |
Cites_doi | 10.1177/000456329703400307 10.1182/blood.V76.7.1341.1341 10.1053/euhj.1998.1312 10.1016/S0735-1097(02)01986-1 10.1056/NEJMoa035003 10.1016/S0002-8703(03)00169-8 10.1111/j.1365-2796.2007.01871.x 10.1161/01.CIR.93.9.1651 10.1161/01.CIR.96.12.4204 10.1161/CIRCULATIONAHA.106.641936 10.1016/j.jacc.2007.08.021 10.1016/S0009-8981(97)06547-9 10.1093/clinchem/41.7.966 |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2009 Elsevier Inc. 2009 INIST-CNRS Copyright Elsevier Sequoia S.A. Jan 1, 2009 |
Copyright_xml | – notice: Elsevier Inc. – notice: 2009 Elsevier Inc. – notice: 2009 INIST-CNRS – notice: Copyright Elsevier Sequoia S.A. Jan 1, 2009 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TS 8FD FR3 K9. M7Z NAPCQ P64 7X8 |
DOI | 10.1016/j.amjcard.2008.08.026 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Physical Education Index Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biochemistry Abstracts 1 Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Nursing & Allied Health Premium Technology Research Database Biochemistry Abstracts 1 ProQuest Health & Medical Complete (Alumni) Engineering Research Database Physical Education Index Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Nursing & Allied Health Premium MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1913 |
EndPage | 28 |
ExternalDocumentID | 1623306231 10_1016_j_amjcard_2008_08_026 19101224 21003227 S000291490801415X 1_s2_0_S000291490801415X |
Genre | Multicenter Study Comparative Study Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | - 08R 0R 1 1- 123 1B1 1P 1RT 1~. 1~5 23M 3O- 3V. 4.4 457 4G. 53G 55 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8FI 8FJ 8G5 8P 9JM AABNK AACTN AAEDT AAIAV AAIKJ AAKOC AALMO AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK ABBQC ABFLS ABFNM ABLJU ABLVK ABMAC ABMZM ABOCM ABPIF ABPPZ ABPTK ABUWG ABWYI ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACIWK ACPRK ACRLP ADALY ADBBV ADEZE ADFRT AEBSH AEKER AENEX AEVXI AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AZFZN AZQEC BBAFP BENPR BKEYQ BKOJK BKOMP BLXMC BNPGV BPHCQ BVXVI CS3 DWQXO EBS EFJIC EJD EMOBN EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FO FYUFA G- G-2 G-Q GBLVA GJ GNUQQ GUQSH HEB HMK HMO HVGLF HZ IH2 IHE IPNFZ J1W J5H K K-O KOM L7B LCYCR M M1P M29 M2O M41 MO0 N9A NAPCQ O-L O9- OA. OAUVE OHT OL OVD OZT P-8 P-9 P2P PADUT PC. PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q38 R2- RIG ROL RPZ SAE SDF SDG SEL SES SJN SPCBC SSH SSZ SV3 T5K TEORI TWZ UNMZH UV1 WH7 WOW WUQ X7M XPP YFH YOC YQJ YZZ Z5R ZA5 ZGI ZXP --- --K --M .1- .55 .FO .GJ .~1 0R~ 1CY 1P~ 8P~ AAEDW ABJNI ADMUD AHPSJ AXJTR CCPQU EFLBG FYGXN HMCUK HZ~ OL~ UKHRP YYP ~G- AAUGY AKALU IQODW AKRWK CGR CUY CVF ECM EIF NPM AAXKI AAYXX ADUKH AFCTW ALIPV CITATION 7TS 8FD FR3 K9. M7Z P64 7X8 |
ID | FETCH-LOGICAL-c475t-4ad21e0176608e9f097352379325baaf2470c891218307bd8bce196ecbbb396f3 |
IEDL.DBID | .~1 |
ISSN | 0002-9149 |
IngestDate | Fri Aug 16 06:17:39 EDT 2024 Fri Sep 13 09:21:34 EDT 2024 Thu Sep 12 16:29:44 EDT 2024 Thu May 23 23:13:17 EDT 2024 Sun Oct 22 16:04:53 EDT 2023 Fri Feb 23 02:27:28 EST 2024 Thu Aug 18 17:13:05 EDT 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Human Pain Prognosis Acute Surgical approach Thorax Circulatory system Hospital Cardiology |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c475t-4ad21e0176608e9f097352379325baaf2470c891218307bd8bce196ecbbb396f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 19101224 |
PQID | 230380681 |
PQPubID | 41200 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_66746968 proquest_journals_230380681 crossref_primary_10_1016_j_amjcard_2008_08_026 pubmed_primary_19101224 pascalfrancis_primary_21003227 elsevier_sciencedirect_doi_10_1016_j_amjcard_2008_08_026 elsevier_clinicalkeyesjournals_1_s2_0_S000291490801415X |
PublicationCentury | 2000 |
PublicationDate | 2009 2009-Jan-01 2009-01-00 20090101 |
PublicationDateYYYYMMDD | 2009-01-01 |
PublicationDate_xml | – year: 2009 text: 2009 |
PublicationDecade | 2000 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States – name: New York |
PublicationTitle | The American journal of cardiology |
PublicationTitleAlternate | Am J Cardiol |
PublicationYear | 2009 |
Publisher | Elsevier Inc Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: Elsevier Limited |
References | Tello-Montoliu, Marin, Roldan, Mainar, Lopez, Sogorb, Vicente, Lip (bib9) 2007; 262 Brennan, Penn, Van Lente, Nambi, Shishehbor, Aviles, Goormastic, Pepoy, McErlean, Topol (bib5) 2003; 349 Verheggen, de Maat, Cats, Haverkate, Zwinderman, Kluft, Bruschke (bib11) 1999; 20 O'Donoghue, de Lemos, Morrow, Murphy, Buros, Cannon, Sabatine (bib3) 2006; 114 Lawler, Bovill, Stump, Collen, Mann, Tracy (bib12) 1990; 76 Lindahl, Venge, Wallentin (bib2) 1996; 93 Kilcullen, Viswanathan, Das, Morrell, Farrin, Barth, Hall (bib8) 2007; 50 Rabitzsch, Mair, Lechleitner, Noll, Hofmann, Krause, Dienstl, Puschendorf (bib7) 1995; 41 Ishii, Nagamura, Nomura, Wang, Taga, Kinoshita, Kurokawa, Iwase, Kondo, Watanabe (bib13) 1997; 262 Menown, Mathew, Gracey, Nesbitt, Murray, Young, Adgey (bib1) 2003; 145 Jernberg, Stridsberg, Venge, Lindahl (bib4) 2002; 40 Toss, Lindahl, Siegbahn, Wallentin (bib10) 1997; 96 Wodzig, Pelsers, van der Vusse, Roos, Glatz (bib6) 1997; 34 19406283 - Am J Cardiol. 2009 May 1;103(9):1329-30 Lawler (10.1016/j.amjcard.2008.08.026_bib12) 1990; 76 Jernberg (10.1016/j.amjcard.2008.08.026_bib4) 2002; 40 Brennan (10.1016/j.amjcard.2008.08.026_bib5) 2003; 349 Tello-Montoliu (10.1016/j.amjcard.2008.08.026_bib9) 2007; 262 Ishii (10.1016/j.amjcard.2008.08.026_bib13) 1997; 262 O'Donoghue (10.1016/j.amjcard.2008.08.026_bib3) 2006; 114 Kilcullen (10.1016/j.amjcard.2008.08.026_bib8) 2007; 50 Verheggen (10.1016/j.amjcard.2008.08.026_bib11) 1999; 20 Menown (10.1016/j.amjcard.2008.08.026_bib1) 2003; 145 Wodzig (10.1016/j.amjcard.2008.08.026_bib6) 1997; 34 Lindahl (10.1016/j.amjcard.2008.08.026_bib2) 1996; 93 Rabitzsch (10.1016/j.amjcard.2008.08.026_bib7) 1995; 41 Toss (10.1016/j.amjcard.2008.08.026_bib10) 1997; 96 |
References_xml | – volume: 93 start-page: 1651 year: 1996 end-page: 1657 ident: bib2 article-title: Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease publication-title: Circulation contributor: fullname: Wallentin – volume: 76 start-page: 1341 year: 1990 end-page: 1348 ident: bib12 article-title: Fibrin fragment publication-title: Blood contributor: fullname: Tracy – volume: 145 start-page: 986 year: 2003 end-page: 992 ident: bib1 article-title: Prediction of Recurrent Events by publication-title: Am Heart J contributor: fullname: Adgey – volume: 20 start-page: 567 year: 1999 end-page: 574 ident: bib11 article-title: Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function publication-title: Eur Heart J contributor: fullname: Bruschke – volume: 50 start-page: 2061 year: 2007 end-page: 2067 ident: bib8 article-title: Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values publication-title: J Am Coll Cardiol contributor: fullname: Hall – volume: 41 start-page: 966 year: 1995 end-page: 978 ident: bib7 article-title: Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury publication-title: Clin Chem contributor: fullname: Puschendorf – volume: 114 start-page: 550 year: 2006 end-page: 557 ident: bib3 article-title: Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes publication-title: Circulation contributor: fullname: Sabatine – volume: 40 start-page: 437 year: 2002 end-page: 445 ident: bib4 article-title: N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation publication-title: J Am Coll Cardiol contributor: fullname: Lindahl – volume: 262 start-page: 651 year: 2007 end-page: 658 ident: bib9 article-title: A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin publication-title: J Intern Med contributor: fullname: Lip – volume: 96 start-page: 4204 year: 1997 end-page: 4210 ident: bib10 article-title: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease publication-title: Circulation contributor: fullname: Wallentin – volume: 34 start-page: 263 year: 1997 end-page: 268 ident: bib6 article-title: One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein publication-title: Ann Clin Biochem contributor: fullname: Glatz – volume: 262 start-page: 13 year: 1997 end-page: 27 ident: bib13 article-title: Early detection of successful coronary reperfusion based on serum concentration of human heart-type cytoplasmic fatty acid-binding protein publication-title: Clin Chim Acta contributor: fullname: Watanabe – volume: 349 start-page: 1595 year: 2003 end-page: 1604 ident: bib5 article-title: Prognostic value of myeloperoxidase in patients with chest pain publication-title: N Engl J Med contributor: fullname: Topol – volume: 34 start-page: 263 year: 1997 ident: 10.1016/j.amjcard.2008.08.026_bib6 article-title: One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein publication-title: Ann Clin Biochem doi: 10.1177/000456329703400307 contributor: fullname: Wodzig – volume: 76 start-page: 1341 year: 1990 ident: 10.1016/j.amjcard.2008.08.026_bib12 article-title: Fibrin fragment d-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction publication-title: Blood doi: 10.1182/blood.V76.7.1341.1341 contributor: fullname: Lawler – volume: 20 start-page: 567 year: 1999 ident: 10.1016/j.amjcard.2008.08.026_bib11 article-title: Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function publication-title: Eur Heart J doi: 10.1053/euhj.1998.1312 contributor: fullname: Verheggen – volume: 40 start-page: 437 year: 2002 ident: 10.1016/j.amjcard.2008.08.026_bib4 article-title: N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(02)01986-1 contributor: fullname: Jernberg – volume: 349 start-page: 1595 year: 2003 ident: 10.1016/j.amjcard.2008.08.026_bib5 article-title: Prognostic value of myeloperoxidase in patients with chest pain publication-title: N Engl J Med doi: 10.1056/NEJMoa035003 contributor: fullname: Brennan – volume: 145 start-page: 986 year: 2003 ident: 10.1016/j.amjcard.2008.08.026_bib1 article-title: Prediction of Recurrent Events by d-Dimer and Inflammatory Markers in Patients With Normal Cardiac Troponin I (PREDICT) study publication-title: Am Heart J doi: 10.1016/S0002-8703(03)00169-8 contributor: fullname: Menown – volume: 262 start-page: 651 year: 2007 ident: 10.1016/j.amjcard.2008.08.026_bib9 article-title: A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin d-dimer levels publication-title: J Intern Med doi: 10.1111/j.1365-2796.2007.01871.x contributor: fullname: Tello-Montoliu – volume: 93 start-page: 1651 year: 1996 ident: 10.1016/j.amjcard.2008.08.026_bib2 article-title: Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease publication-title: Circulation doi: 10.1161/01.CIR.93.9.1651 contributor: fullname: Lindahl – volume: 96 start-page: 4204 year: 1997 ident: 10.1016/j.amjcard.2008.08.026_bib10 article-title: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease publication-title: Circulation doi: 10.1161/01.CIR.96.12.4204 contributor: fullname: Toss – volume: 114 start-page: 550 year: 2006 ident: 10.1016/j.amjcard.2008.08.026_bib3 article-title: Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.641936 contributor: fullname: O'Donoghue – volume: 50 start-page: 2061 year: 2007 ident: 10.1016/j.amjcard.2008.08.026_bib8 article-title: Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.08.021 contributor: fullname: Kilcullen – volume: 262 start-page: 13 year: 1997 ident: 10.1016/j.amjcard.2008.08.026_bib13 article-title: Early detection of successful coronary reperfusion based on serum concentration of human heart-type cytoplasmic fatty acid-binding protein publication-title: Clin Chim Acta doi: 10.1016/S0009-8981(97)06547-9 contributor: fullname: Ishii – volume: 41 start-page: 966 year: 1995 ident: 10.1016/j.amjcard.2008.08.026_bib7 article-title: Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury publication-title: Clin Chem doi: 10.1093/clinchem/41.7.966 contributor: fullname: Rabitzsch |
SSID | ssj0001156 |
Score | 2.2833939 |
Snippet | To evaluate the prognostic role of novel biomarkers for the risk stratification of patients admitted with ischemic-type chest pain, a prospective study of 664... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 22 |
SubjectTerms | Acute Disease Aged Biological and medical sciences Biomarkers - blood Cardiology Cardiology. Vascular system Cardiovascular Cardiovascular disease Chest Pain - blood Chest Pain - diagnosis Chest Pain - etiology Electrocardiography Fatty Acid Binding Protein 3 Fatty Acid-Binding Proteins - blood Female Follow-Up Studies Heart attacks Hospitalization Humans Male Medical prognosis Medical sciences Middle Aged Multivariate analysis Myocardial Ischemia - blood Myocardial Ischemia - complications Myocardial Ischemia - diagnosis Natriuretic Peptide, Brain - blood Patient admissions Peptide Fragments - blood Prognosis Prospective Studies Protein Precursors Proteins Risk Factors |
Title | Prognostic Value of a Multimarker Approach for Patients Presenting to Hospital With Acute Chest Pain |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S000291490801415X https://dx.doi.org/10.1016/j.amjcard.2008.08.026 https://www.ncbi.nlm.nih.gov/pubmed/19101224 https://www.proquest.com/docview/230380681/abstract/ https://search.proquest.com/docview/66746968 |
Volume | 103 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Ni9NA9LGsIIKI38bVOgevaWfyMUmOpbhUZZceXO1tmJlMsMVNSpNe_e2-l0xaFhVByCmTIcP7fvO-AN5z57hNKLkVlUeYlGUValnasNJpWvGsEpGl-46ra7m8ST6t0_UZLMZaGEqr9LJ_kOm9tPZvZh6as91mQzW-PCoEBa4oWTFdUwU7KiOk6enPU5oHWjxyNIHp61MVz2w71bdbi4jwKZX4UI-FP-unhzvdItSqYdzF3-3RXi9dPoZH3qBk8-HMT-DM1U_h_pUPmT-DcrVvKJkOl9lX_ePgWFMxzfrC21vKzdmzue8rztCAZauh0WrLVkNhEqo21jVsnC_Cvm2672xuD51jC5q1hRs29XO4ufzwZbEM_WiF0CZZ2oWJLiPhOHWH5LkrKmragy4pMmuUGq2rKMm4zQtBBhTPTJkb65BXnTXGxIWs4hdwXje1ewXMci0KFwsbFXlieYn-W5qWUhphCxNnLoDpCFC1GzpoqDG1bKs8Bvw0THwiGUA2gl2N5aEo0FzruatVQrWR4uo3CgggP-68Q0QK9cO_fjq5g-DjUdEl5ij0sgAuRoyr40HQf4tzLnMRwLvjKvInBV107ZpDq6TMEmpAFMDLgUxOQChEH9d8_f-nvoAHQ3SLroTewHm3P7i3aCR1ZtJzwQTuzT9-Xl7_Ap8UD_g |
link.rule.ids | 315,786,790,4043,4521,24144,27956,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw8DSGBJMQ4nthsPmB17R2PpzksaqYCqxTHzbom-U4jmjFkqpJX_nt3CVOqwkQElKe4lg53fm-fF8AH7i13ESU3IrKw4-KovS1LIxf6jgueVKKwNB9x_xazm6jz8t4eQTToRaG0iqd7O9leiet3Zuxw-Z4s1pRjS8PMkGBK0pWjJcP4CGZ8zS_YfTzkOeBJo8cbGD6_FDGM16P9N3aICVcTiU-1GThzwrqyUY3iLayn3fxd4O0U0yXz-CpsyjZpAf6ORzZ6gU8mruY-UsoFtuasulwmX3VP3aW1SXTrKu8vaPknC2buMbiDC1Ytug7rTZs0VcmoW5jbc2GASPs26r9ziZm11o2pWFbuGFVvYLby48305nvZiv4Jkri1o90EQjLqT0kT21WUtce9EmRW4M417oMooSbNBNkQfEkL9LcWGRWa_I8DzNZhq_huKorewrMcC0yGwoTZGlkeIEOXBwXUubCZHmYWA9GA0LVpm-hoYbcsrVyFHDjMPEJpAfJgHY11IeiRLONY69GCdUEiqvfjoAH6X7nvVOkUEH866fn9wi8BxV9Yo5SL_HgbKC42gOCDlyYcpkKDy72q8igFHXRla13jZIyiagDkQdv-mNyQEImusDm2_-H-gIez27mV-rq0_WXMzjpQ110P_QOjtvtzr5Hi6nNzzuO-AXAOxGK |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Value+of+a+Multimarker+Approach+for+Patients+Presenting+to+Hospital+With+Acute+Chest+Pain&rft.jtitle=The+American+journal+of+cardiology&rft.au=McCann%2C+Conor+J.%2C+MD&rft.au=Glover%2C+Ben+M.%2C+MD&rft.au=Menown%2C+Ian+B.A.%2C+MD&rft.au=Moore%2C+Michael+J.%2C+MD&rft.date=2009&rft.issn=0002-9149&rft.eissn=1879-1913&rft.volume=103&rft.issue=1&rft.spage=22&rft.epage=28&rft_id=info:doi/10.1016%2Fj.amjcard.2008.08.026&rft.externalDocID=1_s2_0_S000291490801415X |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029149%2FS0002914908X00347%2Fcov150h.gif |